News : nail fungus

View:
 

Found press releases

 

FURTHER STUDIES MAY BE REQUIRED FOR MOB-015

2/9/2012 1:59 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (OMX: MOB) has analysed data from approximately fifty per cent of the patients in the ongoing open phase II study for MOB-015. Based on the analysis, the company assesses that there is low probability that the final results from the study will be sufficient for out-licensing the project. Further studies will probably be required before continuing to phase III. The ongoing phase II study will be...

MOBERG DERMA AND MENARINI GROUP SIGN AGREEMENT FOR EMTRIX IN ITALY

12/9/2011 2:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (STO: MOB) has entered into a distribution agreement with Menarini Group for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Menarini’s OTC Division is granted exclusive rights to market and sell Emtrix® in Italy under the trademark YouDerm Emtrix®.
“The agreement is part of our international commercialization of Emtrix®. As...

MOBERG DERMA AND MEDA EXTEND LICENSE AGREEMENT

11/30/2011 8:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (publ.) and Meda have entered into an additional license agreement for Nalox™ - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. The agreement extends Meda's rights to market and sell Nalox™ to Russia, Turkey and several countries in Eastern Europe. Moberg Derma assumes production and supply responsibility.

MOBERG DERMA AND MEDA SIGN AGREEMENT FOR NALOX IN EUROPE

9/19/2011 2:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (OMX: MOB) and Meda AB have entered into a license agreement covering rights for Nalox® - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Meda is granted exclusive rights to market and sell Nalox® in a large number of countries in Europe. Moberg Derma assumes production and supply...

MOBERG DERMA HAS COMPLETED RECRUITMENT FOR MOB-015 PHASE II CLINICAL STUDY

9/12/2011 2:30 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (OMX: MOB) has successfully completed the recruitment of 237 patients with nail fungus (onychomycosis) to participate in the ongoing MOB-015 phase II study. MOB-015 is the company’s second-generation topical treatment for nail fungus.
The purpose of the study, which includes 237 patients, is to confirm the validity of the MOB-015 product concept and to provide the basis for a phase III program...

MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT IN AUSTRALIA AND NEW ZEELAND

6/8/2011 2:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (publ.) has entered into a distribution agreement with OzHealth Pharma for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement OZ Pharma Health is granted exclusive rights to market and sell Emtrix® in Australia and New Zeeland.
”The agreement is part of our international commercialization of Emtrix®, which now will be marketed...

MOBERG DERMA SIGNS LETTER OF INTENT FOR DISTRIBUTION IN THE UNITED STATES

3/29/2011 3:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (publ) has entered into a letter of intent for distribution in the United States. The letter of intent includes Emtrix® – a product for treatment of discolored and deformed nails resulting from fungal infection (onychomycosis) or psoriasis. The intention is to give the distributor an exclusive right to market and sell Emtrix® in the U.S.
"Already the first quarter after launch, Emtrix® is the...

MOBERG DERMA SIGNS DISTRIBUTION AGREEMENTS IN SPAIN AND UK

3/15/2011 4:40 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (publ) has entered into distribution agreements with AG Farma S.A. in Spain and HairXpertise Ltd in UK for Emtrix® – for treatment of discolored and deformed nails resulting from fungal infection (onychomycosis) or psoriasis. Under the agreements, the distributors are granted exclusive rights to market and sell Emtrix®.
”The agreements follow on a positive response in the Nordic market. Already...

MOBERG DERMA REPORTS POSITIVE CLINICAL RESULTS FOR EMTRIX

2/2/2011 4:45 AM EST  -   MOBERG DERMA AB
Moberg Derma AB today reports positive results from a clinical trial of Emtrix. The trial included 75 patients with nail fungus (onychomycosis) and the results showed that 92% of the patients improved after 8 weeks of treatment. Already after 2 weeks, 77% of the patients were improved.
The open clinical trial was conducted at two clinical centers in Sweden during the second half of 2010. The purpose was to...

MOBERG DERMA IS GRANTED PERMIT TO INITIATE PHASE II-TRIAL FOR MOB-015

11/17/2010 2:00 AM EST  -   MOBERG DERMA AB
The Swedish Medical Products Agency has granted Moberg Derma permit to initiate a clinical phase II trial for MOB-015. MOB-015 is Moberg Dermas next generation topical treatment for nail fungus, with fungicidal, keratolytic and emollient properties.
Nail fungus (onychomycosis) chiefly manifests itself in thickening and discoloration of the nails. The disease is common, affecting about 100 million patients in...